Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. [electronic resource]
Producer: 20190219Description: 1035-1038 p. digitalISSN:- 1476-5551
- Adult
- Aged
- Aged, 80 and over
- Benzamides -- therapeutic use
- Female
- Humans
- Janus Kinase 1 -- antagonists & inhibitors
- Janus Kinase 2 -- antagonists & inhibitors
- Male
- Middle Aged
- Primary Myelofibrosis -- drug therapy
- Protein Kinase Inhibitors -- therapeutic use
- Pyrimidines -- therapeutic use
- Thrombocytosis -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.